Elicio Therapeuticsの空売り状況は、投資家がElicio Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, 空売り情報

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

B of A Securities analyst Kalei Akamine downgrades ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Buy to Neutral and lowers the price target from $138 to $107.

News

Downgrades

Price Target

Analyst Ratings

B of A Securities Downgrades ConocoPhillips to Neutral, Lowers Price Target to $107

WIIM

IFRX

InflaRx shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $10.

B of A Securities analyst Kalei Akamine upgrades Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) from Neutral to Buy and lowers the price target from $202 to $170.

Upgrades

FANG

B of A Securities Upgrades Diamondback Energy to Buy, Lowers Price Target to $170

CIBC analyst Hamir Patel maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and lowers the price target from $55 to $47.

MEOH

CIBC Maintains Outperformer on Methanex, Lowers Price Target to $47

B of A Securities analyst Noah Hungness upgrades Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) from Neutral to Buy and lowers the price target from $125 to $114.

CHRD

B of A Securities Upgrades Chord Energy to Buy, Lowers Price Target to $114

UAVS

AgEagle Aerial Systems shares are trading lower after the company announced it received a NYSE non-compliance notice regarding its minimums stockholders equity.

B of A Securities analyst Nat Schindler upgrades Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Underperform to Neutral and maintains the price target from $53 to $53.

UPST

B of A Securities Upgrades Upstart Hldgs to Neutral, Maintains Price Target to $53

TZOO

Travelzoo shares are trading higher following a Q1 revenue beat. Additionally, the company issued Q2 revenue guidance above estimates.

Argus Research analyst John Staszak reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Hold and maintains $490 price target.

Reiteration

Argus Research Reiterates Hold on Domino's Pizza, Maintains $490 Price Target

SAIH

Saiheat shares are trading higher after the company reported a year-over-year increase in FY24 EPS results.

WLDS

Wearable Devices shares are trading higher after the company announced it raised $1.2 million in gross proceeds through a warrant inducement agreement.

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Outperform and raises the price target from $279 to $282.

Keefe, Bruyette & Woods Maintains Outperform on RenaissanceRe Holdings, Raises Price Target to $282

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.44% on an annualized basis producing an average annual return of 21.65%. Currently, Meta Platforms has a market capitalization of $1.39 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $6,983.12 today based on a price of $550.34 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745941512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Market Perform and lowers the price target from $88 to $86.

Keefe, Bruyette & Woods Maintains Market Perform on Principal Financial Group, Lowers Price Target to $86

FISI

Financial Institutions shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Over the past three weeks, shares of Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) have declined by 8%, <a href="https://www.benzinga.com/topic/s-p-500">underperforming the S&amp;P 500</a> by more than 1,000 basis points, according to BofA Securities.
The Progressive Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8bb85e9300015f1ad8/joshua-shanker">Analyst Joshua Shanker</a> upgraded the rating from Neutral to Buy, while raising the price target from $297 to $312.
The Progressive Thesis: Earlier this month, the company announced its March 2025 results, adding a net 572,000 new personal auto customers, representing a month of the highest growth in its history, Shankar said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"It remains to be seen to what degree tariffs will be implemented by the Trump administration, creating uncertainty," the analyst wrote.
Shankar pointed out that supply-chain disruptions during the pandemic and post-pandemic periods resulted in the steepest auto insurance price hikes in 50 years, boosting profitability and market share gains for Progressive. Similarly tariff-induced inflation may act as "a tailwind to Progressive&#8217;s success and PGR stock performance," he further stated.
PGR Price Action: Shares of Progressive had risen by 1.7% to $274.19 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Dividend Investor Making $6,000/Month Shares Portfolio; Bought More on Recent &#8216;Bloody Day&#8217; Selloff — &#8216;Keep Grinding Until We Don&#8217;t Have To&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Movers

Progressive's Pain May Turn To Gain As Tariff Inflation Creates A Surprising Tailwind

Universal Logistics shares are trading lower after Stifel cut its price target on the stock from $37 to $29.

TD Cowen analyst Derick Ma initiates coverage on Faraday Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FDY#TSX">FDY</a>) with a Buy rating and announces Price Target of C$1.25.

Initiation

TSX:FDY

TD Cowen Initiates Coverage On Faraday Copper with Buy Rating, Announces Price Target of C$1.25

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) with a Market Perform and raises the price target from $21 to $23.

Keefe, Bruyette & Woods Maintains Market Perform on PCB Bancorp, Raises Price Target to $23

Scotiabank analyst Brandon Bingham maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Sector Outperform and lowers the price target from $201 to $199.

TRGP

Scotiabank Maintains Sector Outperform on Targa Resources, Lowers Price Target to $199

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Health Care

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Earnings

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

General

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

ELTX

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Caribou Biosciences

CervoMed

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

MediciNova

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vigil Neuroscience

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Elicio Therapeutics

空売り

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル